MET Gene Alterations clinical trials at UC Cancer
1 research study open to eligible people
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
open to eligible people ages 18 years and up
A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. The study will proceed in two parts: a dose-escalation and dose-expansion.
at UC Irvine UCSD